Please try another search
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
Name | Age | Since | Title |
---|---|---|---|
Michael L. Klowden | 77 | 2023 | Independent Director |
Anthony T. Reder | - | 2023 | Member of Scientific Advisory Board |
Craig Blackstone | - | 2023 | Member of Scientific Advisory Board |
Kathleen D. Scott | - | 2023 | Independent Director |
Evren Alici | - | - | Member of Scientific Advisory Board |
Ming Guo | - | 2023 | Member of Scientific Advisory Board |
Yong Ben | 49 | - | Scientific & Clinical Advisor |
Paul Y. Song | 58 | 2023 | CEO & Chairman |
Sangwoo Park | 54 | 2023 | Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review